These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33176842)

  • 1. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis-design, rationale, and methodology of the METEOR-China study.
    Wang Y; Wang A; Li H; Li Z; Hu B; Li X; Zheng H; Fu L; Hu H; Nie Z; Qin Y; Zhao B; Wei D; Karlson BW; Bots ML; Chen Y; Wang Y
    Trials; 2020 Nov; 21(1):921. PubMed ID: 33176842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study.
    Zheng H; Li H; Wang Y; Li Z; Hu B; Li X; Fu L; Hu H; Nie Z; Zhao B; Wei D; Karlson BW; Bots ML; Meng X; Chen Y; Wang Y;
    Stroke; 2022 Oct; 53(10):3004-3013. PubMed ID: 36017704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
    Crouse JR; Raichlen JS; Riley WA; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Bots ML;
    JAMA; 2007 Mar; 297(12):1344-53. PubMed ID: 17384434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis--the rationale and methodology of the METEOR study.
    Crouse JR; Grobbee DE; O'Leary DH; Bots ML; Evans GW; Palmer MK; Riley WA; Raichlen JS;
    Cardiovasc Drugs Ther; 2004 May; 18(3):231-8. PubMed ID: 15229392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study.
    Crouse JR; Bots ML; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Raichlen JS;
    Eur J Cardiovasc Prev Rehabil; 2010 Apr; 17(2):223-9. PubMed ID: 20038840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study.
    Bots ML; Palmer MK; Dogan S; Plantinga Y; Raichlen JS; Evans GW; O'Leary DH; Grobbee DE; Crouse JR;
    J Intern Med; 2009 Jun; 265(6):698-707. PubMed ID: 19298496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. METEOR Trial Reports on the Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals with Subclinical Atherosclerosis.
    Haddad RM; Ballantyne CM
    Phys Sportsmed; 2010 Jun; 38(2):180-2. PubMed ID: 20631478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk.
    Calza L; Manfredi R; Colangeli V; Trapani FF; Salvadori C; Magistrelli E; Danese I; Verucchi G; Serra C; Viale P
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):547-56. PubMed ID: 23098891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologically implausible carotid intima-media thickness measurement values: effects on rate of change over time.
    Peters SA; den Ruijter HM; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Evans GW; Raichlen JS; Bots ML;
    Curr Med Res Opin; 2012 Jun; 28(6):891-9. PubMed ID: 22536884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of 2-year treatment with low-dose rosuvastatin on intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease.
    Riccioni G; Cipollone F; Santovito D; Scotti L; D'Orazio N; Mezzetti A; Bucciarelli T
    Expert Opin Pharmacother; 2011 Dec; 12(17):2599-604. PubMed ID: 21999752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manual or semi-automated edge detection of the maximal far wall common carotid intima-media thickness: a direct comparison.
    Peters SA; den Ruijter HM; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Evans GW; Raichlen JS; Lind L; Bots ML;
    J Intern Med; 2012 Mar; 271(3):247-56. PubMed ID: 21726301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of atherosclerosis in patients living with HIV.
    De Lorenzo F; Boffito M; Collot-Teixeira S; Gazzard B; McGregor JL; Shotliff K; Xiao H
    Vasc Health Risk Manag; 2009; 5(1):287-300. PubMed ID: 19436663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosuvastatin reduces intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease: the Asymptomatic Carotid Atherosclerotic Disease in Manfredonia (ACADIM) Study.
    Riccioni G; Bazzano LA; Bucciarelli T; Mancini B; di Ilio E; D'Orazio N
    Expert Opin Pharmacother; 2008 Oct; 9(14):2403-8. PubMed ID: 18778179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extensive or restricted ultrasound protocols to measure carotid intima-media thickness: analysis of completeness rates and impact on observed rates of change over time.
    Peters SA; den Ruijter HM; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Evans GW; Raichlen JS; Bots ML;
    J Am Soc Echocardiogr; 2012 Jan; 25(1):91-100. PubMed ID: 21982737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of rosuvastatin on the echolucency of the common carotid intima-media in low-risk individuals: the METEOR trial.
    Lind L; Peters SA; den Ruijter HM; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Evans GW; Raichlen JS; Bots ML;
    J Am Soc Echocardiogr; 2012 Oct; 25(10):1120-1127.e1. PubMed ID: 22884641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-reactive protein lowering with rosuvastatin in the METEOR study.
    Peters SA; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Raichlen JS; Bots ML
    J Intern Med; 2010 Aug; 268(2):155-61. PubMed ID: 20412373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.
    Kones R
    Drug Des Devel Ther; 2010 Dec; 4():383-413. PubMed ID: 21267417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of plaque score measurements to assess changes in atherosclerotic plaque burden induced by lipid-lowering therapy over time: the METEOR study.
    Peters SA; Dogan S; Meijer R; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Evans GW; Raichlen JS; Bots ML
    J Atheroscler Thromb; 2011; 18(9):784-95. PubMed ID: 21617330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Algorithms to measure carotid intima-media thickness in trials: a comparison of reproducibility, rate of progression and treatment effect.
    Dogan S; Plantinga Y; Crouse JR; Evans GW; Raichlen JS; O'Leary DH; Palmer MK; Grobbee DE; Bots ML;
    J Hypertens; 2011 Nov; 29(11):2181-93. PubMed ID: 21918474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in carotid intima-media thickness in a high-risk group of patients by intensive lipid-lowering therapy with rosuvastatin: subanalysis of the JART study.
    Yokoi H; Nohara R; Daida H; Hata M; Kaku K; Kawamori R; Kishimoto J; Kurabayashi M; Masuda I; Sakuma I; Yamazaki T; Yoshida M
    Int Heart J; 2014; 55(2):146-52. PubMed ID: 24632963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.